Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am J Gastroenterol. 2023 May 19;118(6):936–954. doi: 10.14309/ajg.0000000000002227

Table 4.

Overview of interventions for the pharmacological management of chronic idiopathic constipation

What medications can be used to treat chronic idiopathic constipation? Mechanism of action Recommended initial dose Guidance for dose titration Maximum dose Estimated monthly cost, USDa Additional comments
Fiber Soluble fiber traps water in the intestine and softens stool Insoluble fiber increases stool bulk The Academy of Nutrition and Dieteticsa recommends 14 g/1,000 kcal intake per day Total daily fiber intake (dietary + supplement) 20–30 g/d Per response to symptoms and side effects Common side effects include bloating and abdominal discomfort Usually no benefit to increasing total fiber intake over 25–30 g <$50 Ensure adequate hydration as fiber intake increases No clear evidence that soluble or insoluble fiber is more effective Soluble fiber includes psyllium, inulin, oats, fruit, barley, and legumes Insoluble fiber includes wheat bran, methylcellulose, wheat, rye, and other grains
Polyethylene glycol Osmotic laxative 17 g daily Per symptom response and side effects Common side effects include bloating, abdominal discomfort, and cramping No clear maximum dose $10-$45 Response to PEG has been shown to be durable over 6 mo
Magnesium oxide Osmotic laxative 400–500 mg daily Per symptom and response and side effects No clear maximum dose. Prior studies used 1,000–1,500 mg daily <$50 Use with caution in patients with renal insufficiency and in pregnancy
Lactulose Osmotic laxative 15 g daily Per symptom response and side effects Bloating and flatulence may be limiting if preexisting symptoms or at higher doses No clear maximum dose. May cause hypernatremia and hypokalemia if patients experience significant diarrhea <$50 Only osmotic agent studied in pregnancy
Bisadocyl and picosulfate Stimulant laxative Bisacodyl 5 mg daily Per symptom response and side effects Side effects limited by cramping and abdominal discomfort 10 mg orally daily <$50 Recommended for short-term use or rescue therapy Prolonged or excessive use can cause diarrhea and electrolyte imbalance Long-term safety and efficacy unknown
Senna Stimulant laxative 8.6–17.2 mg daily Per symptom response and side effects Side effects most commonly cramping and abdominal discomfort No clear maximum dose. Often recommended maximum is 4 tablets twice per day <$50 Also present in many laxative teas, where dose may be difficult to calculate Long-term safety and efficacy unknown
Lubiprostone Intestinal secretagogue acting on chloride channel type 2 in the gut that increases chloride secretion 24 μg BID Per symptom response Diarrhea may occur in a subset of patients, leading to discontinuation 24 μg BID $374 May have benefit for abdominal pain. Also approved for the treatment of IBS-C at a dose of 8 μg BID
Linaclotide Intestinal secretagogue acting on guanylate cyclase-C, which activates CFTR in the gut to increase chloride secretion 72–145 μg daily Per symptom response Diarrhea may occur in a subset of patients, leading to discontinuation 290 μg daily $523 May have benefit for abdominal pain. Also approved for the treatment of IBS-C
Plecanatide Intestinal secretagogue acting on guanylate cyclase-C, which activates CFTR in the gut to increase chloride secretion 3 mg daily Per symptom response Diarrhea may occur in a subset of patients, leading to discontinuation 3 mg daily $526 Also approved for the treatment of IBS-C
Prucalopride 5-HT4 agonist 1 –2 mg daily Per symptom response Headaches and diarrhea may occur in a subset of patients, leading to discontinuation 2 mg daily $563 May have additional benefit for abdominal pain

5-HT4, serotonin type 4; BID, twice a day; IBS-C, irritable bowel syndrome with constipation; PEG, polyethylene glycol; USD, US dollar.

a

The given cost accommodates the extent of generic and prescription medications and may not be the exact cost. In addition, the given cost is not the cost-effectiveness of the medication, but a probable cost per month.